These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9447654)

  • 1. Optimal statistical design for toxicokinetic studies.
    Beatty DA; Piegorsch WW
    Stat Methods Med Res; 1997 Dec; 6(4):359-76. PubMed ID: 9447654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A generalisation of T-optimality for discriminating between competing models with an application to pharmacokinetic studies.
    Vajjah P; Duffull SB
    Pharm Stat; 2012; 11(6):503-10. PubMed ID: 23059829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of robust criteria for D-optimal designs.
    Foo LK; McGree J; Eccleston J; Duffull S
    J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
    Dumont C; Chenel M; Mentré F
    J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of toxicokinetic data to dosage selection in toxicology studies.
    Morgan DG; Kelvin AS; Kinter LB; Fish CJ; Kerns WD; Rhodes G
    Toxicol Pathol; 1994; 22(2):112-23. PubMed ID: 7973359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of an optimal destructive sampling design for noncompartmental AUC estimation.
    Vandenhende F; Comblain M; Delsemme MH; Dewe W; Hoffman WP; Boulanger B
    J Pharmacokinet Biopharm; 1999 Apr; 27(2):191-212. PubMed ID: 10567955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicokinetics in the National Toxicology Program.
    Goehl TJ
    NIDA Res Monogr; 1997; 173():273-304. PubMed ID: 9260193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two design optimality criteria applied to a nonlinear model.
    Bogacka B; Wright F
    J Biopharm Stat; 2004 Nov; 14(4):909-30. PubMed ID: 15587972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal design criteria for discrimination and estimation in nonlinear models.
    Waterhouse TH; Eccleston JA; Duffull SB
    J Biopharm Stat; 2009; 19(2):386-402. PubMed ID: 19212887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal experimental design for a nonlinear response in environmental toxicology.
    Wright SE; Bailer AJ
    Biometrics; 2006 Sep; 62(3):886-92. PubMed ID: 16984332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purpose and guidelines for toxicokinetic studies within the National Toxicology Program.
    Buchanan JR; Burka LT; Melnick RL
    Environ Health Perspect; 1997 May; 105(5):468-71. PubMed ID: 9222127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
    Foo LK; McGree J; Duffull S
    Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal design allocations for estimating area under curves for studies employing destructive sampling.
    Piegorsch WW; Bailer AJ
    J Pharmacokinet Biopharm; 1989 Aug; 17(4):493-507. PubMed ID: 2614683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study design and statistical analysis of toxicokinetics: a report of JPMA investigation of case studies.
    Igarashi T; Yabe T; Noda K
    J Toxicol Sci; 1996 Dec; 21(5):497-504. PubMed ID: 9035061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Importance of Temporal Design: How Do Measurement Intervals Affect the Accuracy and Efficiency of Parameter Estimates in Longitudinal Research?
    Timmons AC; Preacher KJ
    Multivariate Behav Res; 2015; 50(1):41-55. PubMed ID: 26609742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying Bailer's method for AUC confidence intervals to sparse sampling.
    Nedelman JR; Gibiansky E; Lau DT
    Pharm Res; 1995 Jan; 12(1):124-8. PubMed ID: 7724473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models.
    Daimon T; Goto M
    Stat Med; 2007 Jun; 26(14):2799-812. PubMed ID: 17072822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods of robust design of nonlinear models with an application to pharmacokinetics.
    Foo LK; Duffull S
    J Biopharm Stat; 2010 Jul; 20(4):886-902. PubMed ID: 20496212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transform-both-sides nonlinear models for in vitro pharmacokinetic experiments.
    Latif AH; Gilmour SG
    Stat Methods Med Res; 2015 Jun; 24(3):306-24. PubMed ID: 25038072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.